TEZSPIRE^®

 (Tezepelumab) ASTRAZENECA

Composition:⁴

TEZSPIRE® (tezepelumab) for injection in pre-filled syringe or pre-filled pen is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ), administered by subcutaneous injection.

Application:⁴

TEZSPIRE® is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. TEZSPIRE® is not indicated for the relief of acute bronchospasm or status asthmaticus, steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).

References

1. ELREXFIO™. HIGHLIGHTS OF PRESCRIBING INFORMATIONUS 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761345s000lbl.pdf  2. FRUZAQLA™ (fruquintinib). HIGHLIGHTS OF PRESCRIBING INFORMATION. US 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217564s000lbl.pdf  3. MOUNJARO® (tirzepatide). HIGHLIGHTS OF PRESCRIBING INFORMATION. US 2023. https://pi.lilly.com/us/mounjaro-uspi.pdf?s=pi  4. TEZSPIRE® (tezepelumab-ekko) injection. HIGHLIGHTS OF PRESCRIBING INFORMATION. US 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761224s001lbl.pdf